Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.33 USD | -0.19% | -2.49% | -10.98% |
10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
01/05 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.98% | 6.22B | |
+4.92% | 109B | |
+10.91% | 105B | |
-0.38% | 22.25B | |
-12.01% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.05% | 16.85B | |
+4.21% | 13.76B | |
+35.12% | 12.46B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Barclays Adjusts Price Target on Exelixis to $24 From $25, Maintains Overweight Rating